Immix Biopharma, Inc. (IMMX)
Automate Your Wheel Strategy on IMMX
With Tiblio's Option Bot, you can configure your own wheel strategy including IMMX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMMX
- Rev/Share 0.0032
- Book/Share 0.1552
- PB 13.9189
- Debt/Equity 0.2241
- CurrentRatio 1.2313
- ROIC -4.1828
- MktCap 62281678.0
- FreeCF/Share -0.4496
- PFCF -4.6199
- PE -2.8005
- Debt/Assets 0.0667
- DivYield 0
- ROE -2.0535
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
Published: September 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far –
Read More
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference being held on November 11-13, 2025 at the Lotte New York Palace Hotel in New York, NY.
Read More
Immix Biopharma Announces Other Serious Diseases Strategy
Published: August 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) – – Company plans to partner-out Other Serious Disease programs – – On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis – LOS ANGELES, CA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced important updates about its plan to address other serious diseases with its sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 …
Read More
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned – LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced a class-leading safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any grade in low-volume disease to-date, laying a foundation for potential future indication expansion. “We …
Read More
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
Published: July 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
– National Footprint of NEXICART-2 Trial Sites Expanded – – On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/refractory AL Amyloidosis. NEXICART-2 now includes 18 clinical trial sites in its national footprint.
Read More
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Immix Biopharma Attends FDA CEO Forum in Washington DC
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D.
Read More
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Immix Biopharma today presented results at ASCO from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201, meeting its primary endpoint.
Read More
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone adds 10 sites since the Company's most recent update.
Read More
About Immix Biopharma, Inc. (IMMX)
- IPO Date 2021-12-16
- Website https://www.immixbio.com
- Industry Biotechnology
- CEO Ilya Rachman MBA,
- Employees 18